title: Primary bone lymphoma: a clinicopathological retrospective study of 28 patients in a single institution.
abstract: BACKGROUND
  Primary bone lymphoma (PBL) is a rare disease and distinct clinicopathological entity. The optimal treatment strategy is still unclear. Because of rarity of PBL, we report our institute experience in PBL clinicopathological feature and treatment results.
  
  
  METHODS
  28 patients diagnosed with PBL were referred to Omid Hospital, cancer research center (CRC), between March 2001 and February 2009. Immunophenotype studies on 16 out of 28 pathological blocks were performed. We analyzed disease free survival (DFS) and overall survival (OS) rates.
  
  
  RESULTS
  14 patients with PBL were analyzed retrospectively. 17 patients (60.7%) were male and 11 (39.3%) were female with a median age of 41 years (range: 11-79). Long bones were the most primarily site of involvement (71%). 26 (93%) patients had diffuse large B cell lymphoma and 2 (7%) had small lymphoblastic lymphoma. One (3%) patient received radiation alone, 18 (66%) cases received combined modality (chemotherapy + radiotherapy) and 8 (30%) received only chemotherapy during their treatment period. The median follow up was 18 months (range: 1-82). Mean DFS was 51 months (range: 37-66). Overall survival (OS) was 54 months (range: 40-68). OS was significantly better in the chemoradiotherapy group compared with other two groups (64 versus 27 months, respectively, p=0.014). DFS was also significantly better in combined modality arm compared with other two groups (64 versus 21 months, respectively, p=0.003).
  
  
  CONCLUSIONS
  In spite of small number of patients reported in this study, combined modality treatment (chemotherapy and radiotherapy) was shown to be useful as an effective treatment strategy in PBL.
authors.affiliation: Cancer research center (C.R.C), Radiation Oncology Department, Omid Hospital, Mashhad University of Medical Science, Mashhad, Iran.
authors.forename: Mohammad Reza Ghavam
authors.initials: MR
authors.lastname: Nasiri
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Varshoee
authors.forename: Samira
authors.initials: S
authors.lastname: Mohtashami
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Raziee
authors.forename: Amir
authors.initials: A
authors.lastname: Aledavood
authors.forename: Kamran
authors.initials: K
authors.lastname: Ghafarzadeh
authors.forename: Bahram
authors.initials: B
authors.lastname: Memar
authors.forename: Soheil
authors.initials: S
authors.lastname: Vojdani
authors.forename: Mostafa
authors.initials: M
authors.lastname: Sarvizadeh
references.citation: Int Orthop. 1994 Jun;18(3):180-3
references.pmid: 7927969
references.citation: Jpn J Clin Oncol. 2007 Mar;37(3):216-23
references.pmid: 17472971
references.citation: Haematologica. 2003 Mar;88(3):280-5
references.pmid: 12651266
references.citation: Ann Oncol. 2007 Jan;18(1):129-135
references.pmid: 17018705
references.citation: Leukemia. 1999 Dec;13(12):2094-8
references.pmid: 10602434
references.citation: Cancer. 2006 Jun 15;106(12):2652-6
references.pmid: 16700039
references.citation: Int J Oncol. 2006 Jun;28(6):1571-5
references.pmid: 16685458
references.citation: Cancer. 1972 Jan;29(1):252-60
references.pmid: 5007387
references.citation: Indian J Pathol Microbiol. 2010 Apr-Jun;53(2):267-70
references.pmid: 20551530